Comparative Pharmacology
Head-to-head clinical analysis: ATHENTIA NEXT versus NORQUEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHENTIA NEXT versus NORQUEST FE.
ATHENTIA NEXT vs NORQUEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing.
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Category C
Category C
Oral Contraceptive
Oral Contraceptive